The role of CD30 in the pathogenesis of haematopoietic malignancies

Current Opinion in Pharmacology
Aymen Al-Shamkhani

Abstract

CD30, a member of the tumour necrosis factor receptor superfamily, is overexpressed by malignant cells of Hodgkin's lymphoma and by anaplastic large cell lymphoma. CD30 overexpression has been attributed, at least in part, to constitutive expression of JunB, a transcription factor belonging to the AP-1 family that binds to the CD30 promoter. Overexpression of CD30 in Hodgkin's lymphoma cells is thought to result in ligand-independent signaling, leading to activation of nuclear factor-kappaB and survival of the malignant cells. In anaplastic large cell lymphoma, CD30 triggering induces growth arrest and, under certain circumstances, cell death. Finally, transmembrane signalling by CD30 might be regulated by a soluble form of CD30 that is released by proteolytic cleavage of membrane-anchored CD30.

Citations

Jul 12, 2013·Fukushima Journal of Medical Science·Osamu Suzuki, Masafumi Abe
Dec 1, 2011·Expert Opinion on Investigational Drugs·Antonio Gualberto
Sep 25, 2012·Expert Opinion on Drug Discovery·Georg HopfingerOlaf Merkel
Mar 14, 2012·Best Practice & Research. Clinical Haematology·Bettina BisigLaurence de Leval
May 22, 2007·American Journal of Clinical Pathology·L Jeffrey Medeiros, Kojo S J Elenitoba-Johnson
Dec 20, 2015·International Journal of Cancer. Journal International Du Cancer·Fatemeh Saberi HosnijehRoel Vermeulen
Jan 26, 2010·Biochemical Pharmacology·Hans-Peter Gerber
Jan 13, 2011·American Journal of Reproductive Immunology : AJRI·Bárbara LoureiroPeter J Hansen
Nov 21, 2007·Critical Reviews in Oncology/hematology·Yvette L Kasamon, Richard F Ambinder
Dec 19, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Manthana MichaiSeiji Okada
Jul 12, 2011·Biochemical and Biophysical Research Communications·Margarita FernándezSusana Alemany
Nov 30, 2011·Progress in Polymer Science·Kuen Yong Lee, David J Mooney
Jul 30, 2014·The American Journal of Dermatopathology·Paul R MasseyAdam I Rubin
Jul 9, 2016·Applied Immunohistochemistry & Molecular Morphology : AIMM·Tetsuya TabataTadashi Yoshino
Sep 13, 2005·Oncogene·Shao-Cong Sun, Shoji Yamaoka
Aug 1, 2008·Expert Opinion on Drug Discovery·Nishikant V Wase, Phillip C Wright
Jul 23, 2011·Chemical Biology & Drug Design·Shailza SinghBalu A Chopade
Nov 30, 2019·Biochemistry and Molecular Biology Education : a Bimonthly Publication of the International Union of Biochemistry and Molecular Biology·Chun Wu, Tyler S McCune
Feb 6, 2017·Genomics & Informatics·Surya Narayan RathSukanta Kumar Pradhan
May 9, 2014·Applied Immunohistochemistry & Molecular Morphology : AIMM·Meghna AlimchandaniMarkku Miettinen
Aug 21, 2007·British Journal of Pharmacology·A R M Coates, Y Hu
Feb 28, 2007·The American Journal of Surgical Pathology·Elias DrakosGeorge Z Rassidakis
Jul 5, 2019·International Journal of Molecular Sciences·Heidi Abrahamse, Nicolette Nadene Houreld
Apr 22, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Johan GaraudeMartin Villalba
Nov 23, 2019·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·María Queralt SalasEva González-Barca
Jan 31, 2021·Molecular Cancer Research : MCR·Sudhakiranmayi KuraviRamesh Balusu
Jan 1, 2008·Annals of Diagnostic Pathology·Mark R Wick

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.